Citigroup Inc Immunic, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$3.0 - $5.49 $864 - $1,581	-288 Reduced 46.91%	326 $1,000
Q2 2022 Aug 10, 2022	SELL	$3.13 - $12.25 $2,478 - $9,702	-792 Reduced 56.33%	614 $2,000
Q1 2022 May 12, 2022	SELL	$9.54 - $14.26 $39,295 - $58,736	-4,119 Reduced 74.55%	1,406 $16,000
Q4 2021 Feb 10, 2022	BUY	$7.34 - $10.25 $11,332 - $15,826	1,544 Added 38.78%	5,525 $53,000
Q3 2021 Nov 10, 2021	BUY	$8.05 - $13.29 $32,047 - $52,907	3,981 New	3,981 $35,000

56M

4.7K

311K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $36.1M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.